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Epidermal growth factor, oestrogen and progesterone receptor expression
in primary ovarian cancer: correlation with clinical outcome and response
to chemotherapy
G Scambia, P Benedetti-Panici, G Ferrandina, M Distefano, G Salerno, ME Romanini,
A Fagotti and S Mancuso
Department ofGynecology and Obstetrics, Catholic University, Rome, Italy.
Summary The expression of epidermal growth factor receptor (EGFR), oestrogen receptor (ER) and pro-
gesterone receptor (PR) was assayed by a radioreceptor method in 117 primary ovarian cancers. EGFR was
not significantly related to any of the clinicopathological parameters examined. In patients with stage II-IV
disease who underwent second-look surgery after primary chemotherapy, a significant correlation between high
EGFR levels and poor response to chemotherapy was demonstrated (P = 0.031). Moreover, post-operative
residual tumour showed an independent role in predicting chemotherapy response (P = 0.0007) and EGFR
status showed a borderline significance (P = 0.052) in the multivariate analysis. No correlation between steroid
hormone receptors and clinicopathological parameters was observed. Whereas a significant relationship was
shown between EGFR positivity and a shorter overall survival (OS) (P = 0.0022) and progression-free survival
(PFS) (P = 0.0033), patient survival was not related to steroid hormone receptor status. Among the parameters
tested only stage, ascites and EGFR status retained an independent prognostic value in the multivariate
analysis.
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Experimental evidence has shown that the EGF/EGFR
system is involved in ovarian cancer cell growth regulation
(Berchuck et al., 1990; Scambia et al., 1991). At present,
although EGFR expression has been widely demonstrated in
ovarian cancer (Bauknecht et al., 1988; Battaglia et al., 1989;
Berchuck et al., 1991; Stewart et al., 1992; van der Burg et
al., 1993), few studies have investigated the prognostic
significance of EGFR (Bauknecht et al., 1988; Berchuck et
al., 1991; van der Burg et al., 1993). Some evidence does,
however, demonstrate that high EGFR levels may be a
negative prognostic indicator in many tumour types (Sains-
bury et al., 1987; Neal et al., 1991; Maurizi et al., 1992;
Scambia et al., 1994). Moreover, in breast cancer EGFR
expression seems to be a feature of hormone-independent
aggressive clinical behaviour (Klijn et al., 1992). Our previous
study (Scambia et al., 1992) on a series of advanced ovarian
carcinomas demonstrated higher EGFR levels in omental
metastases than in primary tumours. We also reported that
high EGFR levels were significantly associated with a greater
risk of progression.
Data on the role of the expression of oestrogen receptor
(ER) and progesterone receptor (PR) in ovarian cancer are
discordant, although many authors have demonstrated that
positivity for steroid hormone receptors is associated with a
better prognosis (Harding et al., 1990; Rose et al., 1990;
Sevelda et al., 1990; Slotman et al., 1990). In this report the
prognostic significance of EGFR, ER and PR was simul-
taneously analysed in a large prospective series of primary
ovarian cancer patients observed for a long follow-up period.
Patients and methods
Our study included 117 primary ovarian cancer patients
admitted to the Department of Gynecology of the Catholic
University of Rome. All patients were staged according to
the FIGO (1987) (International Federation of Gynecology
and Obstetrics) classification. The World Health Organiza-
tion (WHO) histological typing of ovarian tumours (Serov
and Scully, 1973) was adopted. The clinicopathological
features of the patients are listed in Table I. Chemotherapy
was started 2-3 weeks after surgery. All patients received
cisplatin-containing regimens (Benedetti Panici et al., 1993).
Gynaecological examination, abdominopelvic ultrasonog-
raphy, CA125 assay and radiological investigations, if neces-
sary, were performed monthly for the clinical assessment of
response, which was recorded according to WHO criteria
(WHO, 1979). About 28 days after the last course, clinically
complete responders underwent second-look laparoscopy. In
laparoscopy-negative cases, second-look laparotomy was per-
formed for the assessment of pathological response. During
laparotomy and after peritoneal washings and careful inspec-
tion of the abdominal cavity, biopsy of all suspicious lesions
was performed, and, in the case of no evidence of disease, at
least 20 random biopsies were taken. Patients who initially
had only an explorative laparotomy underwent a second
laparotomy after chemotherapy, and a second cytoreduction
was attempted. Pathologically complete responders received
no further therapy, and all other patients were treated ac-
cording to ongoing phase II studies (Benedetti Panici et al.,
1990).
Processing of tumour tissue
Tissue specimens collected during primary surgery were
frozen on dry ice shortly after surgical removal and stored at
- 80°C until processed. A representative section of specimens
was retained for histopathological examination.
The membrane fraction and cytosol were prepared as des-
cribed elsewhere (Scambia et al., 1992). Briefly, tumour speci-
mens were finely minced and homogenised in five volumes of
ice-cold buffer consisting of 25 mM Tris, 1.5 mM EDTA,
5 mM sodium azide, 20% glycerol (TENG) plus 0.1%
monothioglycerol, by applying several intermittent bursts of
an Ultra-Turrax homogeniser. The crude homogenate was
centrifuged at 7000 g for 20 min at 0°C in order to separate
nuclear fraction from the cytosol fraction. The supernatants
were then centrifuged at 105 000 g for 75 min at 0°C, obtain-
ing the membrane pellet and the cytosolic fraction.
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No. (fmolmg' protein) > 1.5 (%)
Total 117 1.5 0-14.8 63 54
Age (years)
<40 12 1.3 0-4.1 6 50
40-60 69 1.5 0-14.8 35 51
>60 39 1.7 0-12.2 22 61
FIGO stage
I 14 1.4 0- 12.2 7 50
II 8 2.0 0-3.9 4 50
III 80 1.5 0-14.8 44 55
IV 15 1.8 0.3-10.5 9 60
Grade of differentiation
GI-G2 28 2.0 0-10.5 17 61
G3 89 1.5 0-14.8 46 52
Histology
Serous 83 1.5 0-14.8 45 54
Mucinous 6 2.7 0-5.3 4 67
Endometrioid 16 2.8 0-12.2 9 56
Undifferentiated 6 0.7 0-6.3 2 33
Other 6 3.3 0.9-10.2 4 67
Ascites
No 43 1.1 0-12.2 16 37
Yes 74 1.9 0- 10.5 49 66
Residual tumour (cm)
<0.5 61 1.5 0-14.8 33 53
0.5-2 24 1.5 0-4.3 14 58
>2 32 2.2 0-10.5 18 57
['25I]EGFbinding measurement
The membrane pellet was resuspended in TENG plus 10 mM
magnesium chloride. Aliquots of the purified suspension
(100 Il containing 300-500 yg of protein) were incubated
with [125I]EGF (NEN Dupont De Nemours) (3.2 nM) in the
presence or absence of unlabelled EGF (1 AM) for 16 h at
room temperature in a final volume of 4001Jl. Binding was
stopped by the addition of 3 ml of TENG plus 0.1% bovine
serum albumin. Pellets were obtained by centrifugation at
2000 g for 20 min at 0°C and counted in a gamma-counter
for 1 min. Results were expressed as fmoles per mg ofmemb-
rane protein (fmol mg-' protein).
In some cases Scatchard analysis of binding data was
performed according to the previously described protocol
(Scambia et al., 1992). Dissociation constant (Kd) values
ranged from 0.52 to 2.0 nmol 1-l. Protein concentration was
measured by the Bradford method (1976). An EGFR level of
1.5 fmolmg-' protein was chosen as the cut-off value to
define EGFR status.
ER and PR measurement
ER and PR were assayed with the dextran-coated charcoal
(DCC) method according to the EORTC (1980) protocol and
the cytosol fraction (1-2 mg protein ml-') was incubated
(overnight at 4°C) with increasing concentrations of [3H]oest-
radiol ([3H]E2) (sp.act. 120 Ci mmol-' from 0.05 nM to 1 nM)
or [3H]Organon 2058 (sp.act. 49 Ci mmolh' from 0.5 nM to
8 nM) (Amersham International) as radiolabelled compounds.
ER and PR levels of 5.0fmolmg'1 protein and 10.0fmol
mg-' protein were arbitrarily chosen to define ER and PR
status.
Statistical analysis
The Wilcoxon rank sum non-parametric test was used to
analyse the relationship between ER, PR and EGFR expres-
sion and clinicopathological characteristics.
In order to normalise the variance of error the receptor
data were transformed into logl0 of data before performing
Pearson's correlation test (Altman, 1991).
All medians and life tables were computed using the
product-limit estimate of Kaplan and Meier (1958) and the
curves were examined by means of the log-rank test (Mantel,
1966). Multivariate analysis was performed by the Coxpro-
portional hazards model (Cox 1972). Progression-free sur-
vival (PFS) and overall survival (OS) were calculated from
the date of first surgery to the date of clinical or pathological
progression or death. The median follow-up was 19 months
(range 2-110 months).
Results
The distribution of EGFR levels in 117 primary ovarian
tumours is shown in Figure 1. EGFR levels were skewed
towards the lower values and ranged from 0 to 14.8 fmol
mg-' protein, with a median value of 1.5 fmolmg-' protein.
Sixty-three (54%) of the tumours were considered to be
EGFR positive. Table I shows the distribution of EGFR
levels according to clinicopathological characteristics of the
patients. EGFR expression was not significantly related to
any of the parameters examined.
ER ranged from 0 to 306.8 fmol mg'l protein (median
7.3 fmolmg-' protein) and PR ranged from 0 to 832.8 fmol
mg-' protein (median 4.1 fmolmg-' protein). Using a cut-off
of 5 and 10 fmolmg-I protein respectively, ER positivity was
56% and PR positivity was 35%. No correlation between
steroid receptors and age, stage, grading, histotype or ascites
was observed (Table II). PR expression was higher in
patients with post-operative residual tumour <0.5 cm than
in those with residual tumour >0.5 cm (P = 0.01). Using
data transformed into logarithms, a direct correlation was
found between ER and PR expression (P = 0.017), while no
correlation was observed between EGFR and ER/PR dist-
ribution (data not shown).
Eighty-six patients with stage II IV disease underwent
second-look surgery after primary chemotherapy. Table III
shows the univariate and multivariate analysis of clinical and
biological variables for chemotherapy response in advanced
ovarian carcinoma. There is a significant correlation between
EGFR status and response to chemotherapy. In fact, of 36patients with EGFR-negative tumours, 23 (64%) showed
complete response, while of 50 patients with EGFR-positive
tumours, only 19 (38%) demonstrated complete response
(P = 0.031). Stage of disease, residual tumour and ascites are
also significantly linked to chemotherapy response. More-
over, all parameters were examined in a logistic regression
model in which only post-operative residual tumour showed
an independent role in predicting chemotherapy response
(P=0.0007) and EGFR status showed borderline
significance (P = 0.052).
Survival analysis of ovarian cancer patients was performed
on all patients except four who were lost to follow-up. Dur-
ing the follow-up period 55 patients progressed and 45 died
of disease. Figure 2 shows the survival curves in relation to
receptor status. A significant relationship was shown between
EGFR positivity and a shorter OS (P = 0.0022) (Figure 2a).
The 5 year survival was 63% [95% confidence intervals (CI)
46-80%] for patients with EGFR-negative tumours as com-
pared with 26% (95% CI 7-45%) for those with EGFR-
positive tumours. A highly significant relationship between
EGFR status and PFS was observed (P =0.0033) (Figure
2b). The 5 year PFS was 48% (95% CI 30-66%) in EGFR-
negative cases as compared with 20% (95% CI 6-34%) in
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EGFR-positive cases. No difference in OS or PFS was
observed according to steroid hormone receptor status
(Figure 2c-f).
Different cut-off values for ER and PR were also tested in
the survival analysis, and subsets of ER-positive and/or PR-
positive tumours were considered for survival curves in
ovarian cancer patients. No significant correlation between
ER and/or PR and prognosis was observed (data not shown).
Of the clinicopathological parameters examined, stage of
disease, grade of differentiation, post-operative residual
tumour and ascites were significantly correlated with clinical
outcome of patients in the univariate analysis (Table IV).
The same table shows the results of simultaneous examina-
tion of all parameters in the multivariate analysis, in which
only stage, ascites and EGFR status retained an independent
prognostic value.
Discussion
This study updates and extends our previous report on the
prognostic significance of EGFR in ovarian cancer. EGFR
positivity shows a significant correlation with shorter
progression-free survival and overall survival, demonstrating
an independent role in predicting the clinical outcome of
patients. Previous studies on small series have reported a
correlation between high EGFR levels and poor survival.
Foekens et al. (1990) reported that, in 14 advanced ovarian
cancer patients who experienced progression of disease, 12
expressed EGFR while two were EGFR negative. On the
other hand, eight out of nine patients with no evidence of
disease were EGFR negative and only one expressed detec-
table levels of EGFR. A recent study by the same group (van
der Burg et al., 1993) on a series of 50 ovarian cancers
reported a tendency for patients with high EGFR levels to
have a poor progression-free survival, although the difference
was not statistically significant. Using an immunohis-
tochemical technique, Berchuck et al. (1991) also demon-
strated a negative prognostic role of EGFR expression. The
median survival of patients with EGFR-negative tumours
Table II Distribution of ER and PR levels according to clinicopathological characteristics
ER PR
No. Median Range No. (%) Median Range No. (%)
(fmolmg-' protein) )5 (fmolmg-' protein) > 10
Total 117 7.3 0-306.8 65 (56) 4.1 0-832.8 41 (35)
Age (years)
<40 12 21.1 2-306.8 8 (67) 13.2 0-832.8 7 (58)
40-60 69 5.2 0-135.3 34 (49) 4.1 0-169.4 19 (27)
>60 36 8.0 0-153.0 21 (58) 3.9 0-50.3 13 (36)
FIGO stage
I 14 7.4 0-213.0 8 (57) 9.0 0-50.2 7 (50)
II 8 4.6 0-306.8 3 (38) 15.0 0-272.2 5 (62)
III 80 7.9 0-153.0 46 (58) 2.8 0-832.8 22 (27)
IV 15 5.1 0-42.7 8 (53) 8.8 0-78.0 7 (47)
Grade of differentiation
G1-G2 28 5.6 0-306.8 17 (61) 10.6 0-832.8 15 (54)
G3 89 7.0 0-153.0 49 (55) 3.7 0-272.2 23 (26)
Histology
Serous 83 8.5 0-213.0 53 (64) 3.7 0-832.8 28 (32)
Mucinous 6 0.8 0-5.1 1 (17) 0.4 0-17.1 2 (33)
Endometrioid 16 10.1 0-56.3 9 (56) 5.6 0-115.6 5 (31)
Undifferentiated 6 5.7 2.1-34.4 3 (50) 2.8 0-14.7 2 (33)
Other 6 0.7 0-11.6 1 (17) 18.3 0-78.0 3 (50)
Ascites
No 43 4.7 0-56.3 21 (49) 2.8 0-272.2 19 (44)
Yes 74 7.3 0-306.8 42 (57) 4.9 0-169.4 22 (30)
Residual tumour (cm)
<0.5 61 7.3 0-306.8 36 (59) 9.5* 0-832.8 31 (50)
0.5-2 24 7.9 0-153.0 13 (54) 0.0 0-46.4 3 (14)
>2 32 6.9 0-135.3 18 (57) 4.1 0-169.4 7 (23)
*P-value = 0.010.
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was 40 months as compared with 26 months for patients with
EGFR-positive tumours.
In our study EGFR status proved to be an important
factor predicting response to chemotherapy in advanced
ovarian tumours. In accordance with our data Berchuck et
al. (1991) reported that 5 of 15 (33%) patients who showed
complete response were EGFR negative, while only 8 of 49
(16%) patients who showed complete response were EGFR
positive. Previously Bauknecht et al. (1986) reported that
high intratumoral levels of an EGF-like substance were
associated with poor response rate. There are few data on the
possible link between EGFR expression and chemotherapy
Table III Univariate and multivariate analysis of clinical and biological variables for
chemotherapy response in patients with primary advanced ovarian carcinoma
95% CI Univariate Multivariate
No. CR (%) (%) P-value* P-value
Age (years)
<60 56 26 (46%) 33-59
>60 30 16 (53%) 35-71 NS ----
FIGO stage
II 7 5 (71%) 38-104
III 66 35 (53%) 41-65 0.021 NS
IV 13 2(15%) 4-34
Grade of differentiation
G1-G2 12 6 (50%) 22-78
G3 74 36 (49%) 43-55 NS ----
Residual tumour (cm)
<2 58 37 (64%) 52-76
>--2 28 5 (18%) 4-32 0.0001 0.0007
Ascites
No 26 20 (77%) 61-93
Yes 60 22 (33%) 25-49 0.0014 NS.
EGFR status
Negative 36 23 (64%) 57-71
Positive 50 19 (38%) 25-51 0.031 0.052
ER status
Negative 39 21 (53%) 37-68
Positive 47 21 (45%) 31-59 NS ----
PR status
Negative 58 24 (41%) 28-54
Positive 28 18 (64%) 46-82 NS --- -
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Figure 2 Survival rate according to receptor status in 113 ovarian cancer patients. (a) OS according to EGFR status: EGFR-
positive, 62 entered, 31 died; EGFR-negative, 51 entered, 14 died. (b) PFS according to EGFR status: EGFR-positive, 62 entered,
37 progressed; EGFR-negative, 51 entered, 18 progressed. (c) OS according to ER status: ER-positive, 62 entered, 22 died;
ER-negative, 51 entered, 23 died. (d) PFS according to ER status: ER-positive, 62 entered, 29 progressed; ER-negative, 51 entered,
26 progressed. (e) OS according to PR status: PR-positive, 40 entered, 15 died; PR-negative, 73 entered, 30 died. (f) PFS according
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Table IV Univariate and multivariate analysis ofprognostic variables for OS and PFS in patients with primary ovarian carcinoma
Overall Survival Progression-Free Survival
Five-year Univariate Multivariate Five-year Univariate Multivariate
No. survival(%) 95% CI P-value P-value Survival(%) 95% CI P-value P-value
Age (years)
<60 77 16 29- 63 40 25-55
, 60 36 38 18- 58 NS NS 21 2-40 NS NS
FIGO stage
I-II 20 88 73-103 69 40-98
III-IV 93 35 20- 50 0.001 0.048 25 13-37 0.001 0.074
Grade of
differentiation
G1-G2 27 63 37- 88 60 35-85
G3 86 38 23- 53 0.047 NS 25 13-37 0.014 0.082
Residual tumour
(cm)
<2 81 50 42- 58 40 25-55
>2 32 29 10- 38 0.0041 NS 15 0-30 0.002 NS
Ascites
No 43 75 53- 97 60 37-83
Yes 70 28 14- 42 <0.0001 0.0008 20 8-32 <0.0001 0.0002
EGFR status
Negative 51 63 46- 80 48 30-66
Positive 62 26 7- 45 0.0022 0.014 20 6-34 0.0033 0.030
ER status
Negative 51 37 16- 58 30 13-47
Positive 62 46 28- 64 NS NS 35 19-51 NS NS
PR status
Negative 73 38 19- 57 32 18-46
Positive 40 47 26- 68 NS NS 33 12-54 NS NS
response. Fan et al. (1993) demonstrated that an anti-EGFR
monoclonal antibody had a synergistic antiproliferative effect
with cisplatin in cervical cancer cells, while Christen et al.
(1990) observed that high EGF/EGFR levels enhanced sen-
sitivity to cisplatin in ovarian cancer cells. In this context it is
also worth noting that the erbB-2 gene product, a member of
the EGFR family, is in some way linked to chemosensitivity.
Recent data showed that in ovarian cancer cells sensitivity to
platinum compounds is related to erbB-2-pl85 expression
(Pegram et al., 1983; Wolf et al., 1993). Further studies using
'in vitro' models are needed in order to clarify the possible
link of EGFR to mechanisms of tumour cell resistance to
chemotherapy.
Several studies have reported an inverse correlation
between EGFR and ER/PR expression in breast cancer
(Klijn et al., 1992), which suggests that EGFR expression
may identify tumours unresponsive to endocrine therapy.
However, like' van der Burg et al. (1993), we found no
correlation between EGFR and steroid hormone receptors.
This would suggest that in ovarian neoplasms steroid hor-
mone and EGF receptor expression are independently
regulated.
In our series neither ER nor PR expression showed any
prognostic significance, even for different cut-off values. Nor
did simultaneous expression of ER and PR, which is con-
sidered to imply good functionality of the steroid receptor
machinery, show prognostic significance in these tumour
subsets.
Whereas there is some evidence that ER expression does
not play a prognostic role in ovarian cancer (Harding et al.,
1990; Rose et al., 1990; Sevelda et al., 1990; Slotman et al.,
1990), there is no agreement as to PR expression. Although
some authors have reported that PR expression is a
favourable prognostic factor (Harding et al., 1990; Sevelda et
al., 1990; Slotman et al., 1990; van der Burg et al., 1993), we
were not able to confirm this finding, in agreement with Rose
et al. (1990). Although the discrepancies may be due to
different cut-off values and patient populations, it may be
that PR positivity has only a minor prognostic impact since
steroid hormones play a marginal role in onset and spread of
ovarian cancer. This hypothesis is consistent with the finding
that endocrine therapy is only slightly efficacious in the man-
agement of advanced ovarian cancer (Freedman et al., 1986;
Schwartz et al., 1989).
In conclusion our data indicate that high EGFR levels
have a negative prognostic role in ovarian cancer patients.
Therefore, drugs such as anti-EGFR monoclonal antibodies
and the specific inhibitor of the EGFR tyrosine kinase, which
have been shown to inhibit the growth of cancer cells 'in
vitro' and 'in vivo' (Kurachi et al., 1991; Moreshige et al.,
1991; Fry et al., 1994; Schnurch et al., 1994), may find use in
ovarian cancer therapy.
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